- Development of a large scale asymmetric synthesis of the glucocorticoid agonist BI 653048 BS H3PO4
-
The development of a large scale synthesis of the glucocorticoid agonist BI 653048 BS H3PO4 (1·H3PO4) is presented. A key trifluoromethyl ketone intermediate 22 containing an N-(4-methoxyphenyl)ethyl amide was prepared by an enolization/bromine-magnesium exchange/electrophile trapping reaction. A nonselective propargylation of trifluoromethyl ketone 22 gave the desired diastereomer in 32% yield and with dr = 98:2 from a 1:1 diastereomeric mixture after crystallization. Subsequently, an asymmetric propargylation was developed which provided the desired diastereomer in 4:1 diastereoselectivity and 75% yield with dr = 99:1 after crystallization. The azaindole moiety was efficiently installed by a one-pot cross coupling/indolization reaction. An efficient deprotection of the 4-methoxyphenethyl group was developed using H3PO4/anisole to produce the anisole solvate of the API in high yield and purity. The final form, a phosphoric acid cocrystal, was produced in high yield and purity and with consistent control of particle size.
- Reeves, Jonathan T.,Fandrick, Daniel R.,Tan, Zhulin,Song, Jinhua J.,Rodriguez, Sonia,Qu, Bo,Kim, Soojin,Niemeier, Oliver,Li, Zhibin,Byrne, Denis,Campbell, Scot,Chitroda, Ashish,Decroos, Phil,Fachinger, Thomas,Fuchs, Victor,Gonnella, Nina C.,Grinberg, Nelu,Haddad, Nizar,Jaeger, Burkhard,Lee, Heewon,Lorenz, Jon C.,Ma, Shengli,Narayanan, Bikshandarkoil A.,Nummy, Larry J.,Premasiri, Ajith,Roschangar, Frank,Sarvestani, Max,Shen, Sherry,Spinelli, Earl,Sun, Xiufeng,Varsolona, Richard J.,Yee, Nathan,Brenner, Michael,Senanayake, Chris H.
-
p. 3616 - 3635
(2013/06/04)
-
- STEREOSELECTIVE SYNTHESIS OF CERTAIN TRIFLUOROMETHYL-SUBSTITUTED ALCOHOLS
-
A process for stereoselective synthesis of a compound of Formula (X): wherein: wherein: R1 is an aryl group substituted with one to three substituent groups, wherein each substituent group of R1 is independently C1-C5 alkyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, halogen, carboxy, cyano, or trifluoromethyl, wherein each substituent group of R1 is optionally independently substituted with one to three substituents selected from C1-C3 alkyl, C1-C3 alkoxy, phenyl, and alkoxyphenyl; R2 and R3 are each independently C1-C5 alkyl; R4 is C1-C5 alkyl optionally independently substituted with one to three substituent groups, wherein each substituent group of R4 is independently C1-C3 alkyl, hydroxy, halogen, amino, or oxo; and R5 is a heteroaryl group substituted with one to three substituent groups, wherein each substituent group of R5 is independently C1-C5 alkyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylsulfonylamino, aminosulfonyl, C1- C5 alkylaminosulfonyl, C1-C5 dialkylaminosulfonyl, halogen, hydroxy, carboxy, cyano, trifluoromethyl, trifluoromethoxy, trifluoromethylthio, or C1-C5 alkylthio wherein the sulfur atom is optionally oxidized to a sulfoxide or sulfone.
- -
-
Page/Page column 14-15
(2010/12/29)
-
- SYNTHESIS OF CERTAIN TRIFLUOROMETHYL KETONES
-
A process for synthesis of a compound of Formula (X) wherein R1 is an aryl group substituted with one to three substituent groups, wherein each substituent group of R1 is independently C1-C5 alkyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, halogen, carboxy, cyano, or trifluoromethyl, wherein each substituent group of R1 is optionally independently substituted with one to three substituents selected from C1-C3 alkyl, C1-C3 alkoxy, phenyl, and alkoxyphenyl; and R2 and R3 are each independently C1-C5 alkyl.
- -
-
Page/Page column 15-16
(2010/12/29)
-
- GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF
-
Compounds of Formula I wherein R1, R2, X, and Y are as defined herein, or a tautomer, optical isomer, prodrug, co-crystal, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory, allergic, or proliferative processes in a patient using these compounds.
- -
-
-